about
Structural characterization and kinetics of nitric-oxide synthase inhibition by novel N5-(iminoalkyl)- and N5-(iminoalkenyl)-ornithinesNitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptanNeuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicalsCGRP may play a causative role in migraineCox-2 inhibitor attenuates NO-induced nNOS in rat caudal trigeminal nucleusNeuronal signal substances as biomarkers of migraineMigraine pathogenesis and state of pharmacological treatment optionsSB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat.Evaluation and proposal for optimization of neurophysiological tests in migraine: part 2--neuroimaging and the nitroglycerin test.Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute ischaemic stroke.Human migraine models.Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks.Nitric oxide, human diseases and the herbal products that affect the nitric oxide signalling pathway.RNA Sequencing of Trigeminal Ganglia in Rattus Norvegicus after Glyceryl Trinitrate Infusion with Relevance to Migraine.Smoking as a precipitating factor for migraine: a survey in medical students.How to control NO production in cells: N(omega),N(omega)-dimethyl-L-arginine dimethylaminohydrolase as a novel drug target.Selected confirmed, probable, and exploratory migraine biomarkers.Migraine: emerging treatment options for preventive and acute attack therapy.Is there hope for chronic pain and headache?Current and emerging treatment options for migraine and other primary headache disorders.Nitric Oxide Synthase Inhibitors as Antidepressants.Nitric oxide-related drug targets in headache.Are the current IHS guidelines for migraine drug trials being followed?Migraine is a neuronal disease.Chemical mediators of migraine: preclinical and clinical observations.CGRP and NO in the trigeminal system: mechanisms and role in headache generation.Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience.L-arginine and nitric oxide in CNS function and neurodegenerative diseases.Emerging targets in migraine.Carbon monoxide may be an important molecule in migraine and other headaches.Drugs targeting nitric oxide synthase for migraine treatment.Emerging drugs for migraine treatment.Pathophysiology of Migraine: A Disorder of Sensory Processing.Migraine can be induced by sildenafil without changes in middle cerebral artery diameter.L-arginine binding to nitric-oxide synthase. The role of H-bonds to the nonreactive guanidinium nitrogens.The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion.Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vesselsModulation of nitric oxide synthase by nitric oxide donor compounds in migraine.Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?The effect of i.v. L-NG methylarginine hydrochloride (L-NMMA: 546C88) on basal and acetazolamide (Diamox) induced changes of blood velocity in cerebral arteries and regional cerebral blood flow in man.
P2860
Q27641968-61AB881B-B4AD-4018-8628-790AE4C8C7A1Q28168693-1056998D-B166-42C6-BBC4-EC9EE0A678D3Q28180514-BDC1EAC9-06B9-4509-8EED-25701E7B588EQ28216666-AF658FD2-D4A0-4670-A486-1AB0761C02FFQ28222552-3D5CD9B9-6817-4874-B3EB-D710DC633B12Q28254002-5FE9BEFD-FD4C-45FE-BD45-F832E1A2ED86Q30886663-1D6297E1-C531-4E63-975B-BF962454878CQ30912250-9BE2A160-2B19-4165-B63E-6E3D70CE9AB6Q31134807-AE4124C4-810D-4BC1-A415-525FBEE6475CQ33907931-5E534834-9F4D-4AFD-B970-EE3EEA89137BQ34397694-C9BC9EEB-D4E6-45CF-BF51-075734B81322Q34469372-3D1C3F2F-422D-4FDE-B8BD-FA2095BC91C1Q35206668-06F69E07-27A3-4DE8-964B-C25D91BCB3ECQ36026422-91DE5985-215F-47D4-96B8-91B3CFDB907DQ36259566-76E448C6-39C7-4B02-BD11-A7D334EE7496Q36471209-56BCDF54-764E-4E41-9E57-A664DE73BD04Q36546368-2F0349CC-DD5F-4453-8A31-BD7824B45621Q36580576-9E7133B9-8CF8-48CC-ADAB-2A4C0627F2B3Q36947170-6BDB0C2E-A971-4B81-B8F6-B43C2484E17AQ37610198-A0E8C199-B5DB-4F71-B1AB-07ECAAA4B13AQ37709458-0B67EC9A-2891-4361-AF9E-809FA6B01B16Q37739589-01EF026C-E041-4718-BE9E-682E399D0C13Q37798757-3789F2F2-38C6-4726-BD71-A9CA5C2AF04AQ37821333-DAE326D5-80CE-41E2-A6DB-985EBEB46A67Q37883455-5571C0D1-34C9-45FC-9926-BCB2F0D7D51BQ38025661-4A2EE444-A1F2-49D9-B1F1-01EE55343C3FQ38106681-2C9909AA-C081-4E6C-8926-ECF51D9F2D3BQ38134415-529AD6C9-2CDD-440E-91F2-59A1F98D1627Q38169593-333EB242-A229-4E1B-807B-B7670883A580Q38210891-8A442B4A-D0A7-46CE-9A9F-54ED1339619AQ38211063-EAF80A2E-4BA8-4B68-B7C8-8F8F09F614C5Q38303376-BBCB90F5-588D-41DD-B5F0-3846D6920045Q39127073-D35ACBE3-F1C1-48DE-B672-B420B00BDD6EQ40616175-F9A0455C-9913-4D75-B236-0DEF9B91E5E7Q40932895-AA08A640-AAC7-4BF5-98E2-4E128C3F38E9Q41829270-B5F19DDE-ED16-4D29-8A56-D41AD072C82CQ42186934-AB611425-ABD1-4AC8-B15C-4D5B2346D865Q42459229-C1954F00-DB59-4089-AB39-ECBF6DB95B68Q42613452-459BC3FD-A427-4940-94BB-21BFA0E318CCQ42653933-7F612E31-668C-47A6-BCA3-4491B56FD71E
P2860
description
article publié dans la revue scientifique The Lancet
@fr
im Februar 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 1997
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Nitric oxide synthase inhibition in migraine
@en
Nitric oxide synthase inhibition in migraine
@nl
type
label
Nitric oxide synthase inhibition in migraine
@en
Nitric oxide synthase inhibition in migraine
@nl
prefLabel
Nitric oxide synthase inhibition in migraine
@en
Nitric oxide synthase inhibition in migraine
@nl
P2093
P1433
P1476
Nitric oxide synthase inhibition in migraine
@en
P2093
I Christiansen
L H Lassen
P304
P356
10.1016/S0140-6736(97)80021-9
P407
P50
P577
1997-02-01T00:00:00Z